Seeking Alpha·2025-10-14 11:49Group 1: Papa John's Takeover Bid - Papa John's shares rose nearly 10% after a report of a $64 per share takeover bid from Apollo Global, valuing the company at approximately $2 billion [1][2] - The stock continued to show positive movement, increasing by 3% in premarket trading [2] Group 2: Alzheimer's Diagnostic Test Approval - The U.S. FDA approved Elecsys pTau181, a blood-based biomarker test developed by Roche and Eli Lilly for initial assessment of Alzheimer's disease and cognitive decline [3][4] - This test measures phosphorylated Tau (pTau) 181 protein in human plasma, serving as a key biomarker for Alzheimer's pathology [3][4] - Elecsys pTau181 is noted to potentially reduce the need for more invasive and costly diagnostic procedures like PET and CSF testing [5] Group 3: PayPay's IPO Valuation - PayPay, Japan's leading QR code payment app, is expected to have a valuation exceeding $20 billion in its planned U.S. IPO, potentially occurring as early as December 2025 [5][6] - Investor discussions suggest a floor valuation of 2 trillion yen, with market sources indicating the final figure could surpass 3 trillion yen [6][7] - The optimism surrounding PayPay's valuation is attributed to its dominant position in Japan's digital payments market and recent profitability in SoftBank's financial segment [7]